SCHEMBL24677905

SCHEMBL24677905

CC(C)NC(CCCCNI)C(=O)NC(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ NPY1R P25929 2/20 0.38
▸ NPY5R Q15761 1/20 0.38
▸ MME P08473 1/20 0.38
▸ MMP2 P08253 4/20 0.38
▸ MMP3 P08254 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ KMT2A Q03164 3/20 0.37
▸ CTDSP1 Q9GZU7 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HPGDS O60760 1/20 0.37
▸ CASR P41180 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ NAAA Q02083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21081674 0.89 ALDH1A1 (0.43) TSHRPOLBNPY1RNPY5RMME
SCHEMBL21787144 0.89 ALDH1A1 (0.43) TSHRPOLBNPY1RNPY5RMME
SCHEMBL21787357 0.89 HTR2A (0.44) TSHRPOLBNPY1RNPY5RMME
SCHEMBL22799503 0.86 KDM1A (0.40) TSHRPOLBNPY1RNPY5RMME
SCHEMBL21787147 0.85 MME (0.39) TSHRPOLBNPY1RNPY5RMME
SCHEMBL21081676 0.82 KDM1A (0.38) TSHRPOLBNPY1RNPY5RMME
SCHEMBL21081701 0.80 MME (0.35) TSHRPOLBNPY1RNPY5RMME
SCHEMBL24221036 0.79 OPRK1 (0.36) TSHRPOLBNPY1RNPY5RMME
SCHEMBL24677821 0.78 HTR2A (0.41) TSHRPOLBNPY1RNPY5RMME
SCHEMBL21081699 0.78 HTR2A (0.41) TSHRPOLBNPY1RNPY5RMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220273807-A1 CONJUGATES FOR USE IN METHODS OF TREATING CANCER ASTRAZENECA AB (SE) 2022-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220273807-A1 CONJUGATES FOR USE IN METHODS OF TREATING CANCER CD44, FOLH1, SLC17A5 TSHR 1466/4885POLB 1117/4885NPY1R 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback